48 articles for M Pellecchia
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Screening multicomponent reactions for X-linked inhibitor of apoptosis-baculoviral inhibitor of apoptosis protein repeats domain binder.
University of Pittsburgh
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
Sanford-Burnham Medical Research Institute
Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.
Institute
Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
Sanford-Burnham Medical Research Institute
SAR by interligand nuclear overhauser effects (ILOEs) based discovery of acylsulfonamide compounds active against Bcl-x(L) and Mcl-1.
Sanford-Burnham Medical Research Institute
Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.
Sanford-Burnham Medical Research Institute
Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
Sanford-Burnham Medical Research Institute
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.
Institute For Medical Research
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.
Institute For Medical Research
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.
Institute For Medical Research
Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors.
Institute For Medical Research
Development of paramagnetic probes for molecular recognition studies in protein kinases.
Institute For Medical Research
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.
Institute For Medical Research
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
University of California San Diego
Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.
University of California Riverside
Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors.
Institute For Medical Research
Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist.
University of California
Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
University of California Riverside
Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein.
University of California Riverside
Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1.
University of California Riverside
NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.
University of California
Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.
University of California Riverside
Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy.
TBA
Covalent Inhibitors of Protein-Protein Interactions Targeting Lysine, Tyrosine, or Histidine Residues.
TBA
Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Universita Degli Studi Di Salerno
Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach.
University of California Riverside
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
University of California
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
University of California-Riverside
Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.
Shandong University
One-pot synthesis of 4,6-diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38alpha MAP kinase inhibition.
German University In Cairo
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
Merck Frosst Centre For Therapeutic Research
7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
Tokushima Research Institute
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Piramed Pharma
Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies.
Eli Lilly
The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.
Merck Research Laboratories
Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1).
Pfizer
Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Vernalis (R&D)
Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites.
Universita Di Siena
Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
Merck Research Laboratories